

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

RESIGNATION OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) hereby announces that, Ms. Liu Xiaohan (“**Ms. Liu**”) has resigned as a joint company secretary of the Company with effect from August 19, 2026. Ms. Liu has confirmed that she has no disagreement with the Board and there is no matter in relation to her resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

Immediately following the resignation of Ms. Liu, the other joint company secretary of the Company, Ms. Leung Wing Han Sharon, will remain in office and act as the sole company secretary of the Company.

The Board would like to express its sincere gratitude and appreciation to Ms. Liu for her valuable efforts and contributions to the Company during her tenure of office.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
August 19, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.